U.S. License Holder:
Genentech Inc.
Date of License:
June-20-2024
Last Update:
Nov-30-2024
FDA-Approved Indications
PIASKY (crovalimab-akkz) is a complement C5 inhibitor indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg.